Combined anti-S1 and anti-S2 antibodies from hybrid immunity elicit potent cross-variant ADCC against SARS-CoV-2-Reference-Cited by-同舟云学术

Combined anti-S1 and anti-S2 antibodies from hybrid immunity elicit potent cross-variant ADCC against SARS-CoV-2

Published:2023-08-08 Issue:15 Volume:8 Page:
ISSN:2379-3708
Container-title:JCI Insight
language:en
Short-container-title:

Author:

Grant Michael D.,Bentley Kirsten^ORCID,Fielding Ceri A.^ORCID,Hatfield Keeley M.,Ings Danielle P.,Harnum Debbie,Wang Eddie C.Y.^ORCID,Stanton Richard J.^ORCID,Holder Kayla A.^ORCID

Funder

Canadian Institutes of Health Research

Medical Research Council

Wellcome Trust

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://insight.jci.org/articles/view/170681/files/pdf

Reference71 articles.

1. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine

2. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

3. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

4. SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment

5. Overview of Neutralizing Antibodies and Their Potential in COVID-19

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The S2 subunit of spike encodes diverse targets for functional antibody responses to SARS-CoV-2;PLOS Pathogens;2024-08-02

2. Identification of soluble biomarkers that associate with distinct manifestations of long COVID;2024-06-05

3. Vaccine-elicited immune pressure and SARS-CoV-2 mutational dynamics in breakthrough infections;Gene Reports;2024-06

4. Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies;iScience;2024-04

5. SARS-CoV-2 Vaccine-Elicited Immunity after B Cell Depletion in Multiple Sclerosis;ImmunoHorizons;2024-03-01